Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Leonard, R, O'Shaughnessy, J, Vukelja, S, Gorbounova, V, Chan-Navarro, CA, Maraninchi, D, Barak-Wigler, N, McKendrick, JJ, Harker, WG, Bexon, AS, Twelves, C
Published in Annals of oncology (01.09.2006)
Published in Annals of oncology (01.09.2006)
Get full text
Journal Article